Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
Earnings Data
Report Date
Jul 22, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
2.68Last Year’s EPS
2.82Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 15, 2025
|% Change Since: 0.66%
|Next Earnings Date:Jul 22, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong start to 2025 for Johnson & Johnson, driven by robust sales growth in innovative medicine and MedTech, significant oncology advancements, and strategic investments. However, challenges such as the decline in STELARA sales, tariff impacts, and orthopedics disruptions pose headwinds.Company Guidance
During the Johnson & Johnson First Quarter 2025 Earnings Conference Call, the company provided guidance and reported financial metrics reflecting strong operational sales growth of 4.2% across its business sectors. The innovative medicine segment saw a 4.2% sales increase despite an 810 basis points headwind from the loss of exclusivity on STELARA. Key brands, including DARZALEX, Tremfya, and Ribrofant plus LASCRUZ, showcased robust growth, with DARZALEX exceeding $3 billion in sales and Tremfya achieving 20% growth due to its new indications. The MedTech segment also reported a 4.1% sales increase, driven by strategic acquisitions such as Abiomed and Shockwave. The company raised its operational sales guidance for the full year to reflect the addition of Caplyta, projecting operational sales growth between 3.3% and 4.3%. This guidance incorporates a positive foreign currency impact, resulting in a full-year headwind of $600 million. Johnson & Johnson maintained its adjusted reported earnings per share guidance of $10.50 to $10.70, representing a 6.2% increase at the midpoint, despite challenges such as tariffs and biosimilar competition. The call underscored the company's commitment to innovation, highlighting plans for significant investments in R&D and manufacturing.Strong Operational Sales Growth
Johnson & Johnson delivered a 4.2% operational sales growth in Q1 2025, with significant contributions from innovative medicine and MedTech sectors.
DARZALEX Performance
DARZALEX achieved over 20% growth, with sales above $3 billion for the third consecutive quarter, and expanded its indication in Europe for multiple myeloma.
Oncology Advancements
Riboflavin plus LASCRUZ showed over a year improvement in overall survival for EGFR-mutated lung cancer, and subcutaneous riboflavin was approved in Europe.
Tremfya's Market Impact
Tremfya entered the inflammatory bowel disease market, with a 20% sales growth, and is expected to become a $10 billion-plus product.
MedTech Segment Growth
MedTech delivered 4.1% operational sales growth, with strong performances in cardiovascular businesses and surgical vision.
Significant Investment Plans
Johnson & Johnson announced a $55 billion investment in the U.S. over the next four years, including four new manufacturing facilities.
Dividend Increase
The company increased its dividend for the sixty-third consecutive year.
---
JNJ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JNJ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 15, 2025 | $154.36 | $153.62 | -0.48% |
| Jan 22, 2025 | $146.97 | $144.12 | -1.94% |
| Oct 15, 2024 | $159.04 | $161.50 | +1.55% |
| Jul 17, 2024 | $147.50 | $152.94 | +3.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Johnson & Johnson (JNJ) report earnings?
Johnson & Johnson (JNJ) is schdueled to report earning on Jul 22, 2025, TBA Not Confirmed.
What is Johnson & Johnson (JNJ) earnings time?
Johnson & Johnson (JNJ) earnings time is at Jul 22, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JNJ EPS forecast?
JNJ EPS forecast for the fiscal quarter 2025 (Q2) is 2.68.
---
